WO2003097037A1 - Substance attenuant les symptomes allergiques - Google Patents

Substance attenuant les symptomes allergiques Download PDF

Info

Publication number
WO2003097037A1
WO2003097037A1 PCT/JP2003/006241 JP0306241W WO03097037A1 WO 2003097037 A1 WO2003097037 A1 WO 2003097037A1 JP 0306241 W JP0306241 W JP 0306241W WO 03097037 A1 WO03097037 A1 WO 03097037A1
Authority
WO
WIPO (PCT)
Prior art keywords
isoflavones
allergic symptom
allergic
symptom
isoflavone
Prior art date
Application number
PCT/JP2003/006241
Other languages
English (en)
Japanese (ja)
Inventor
Mikako Takasugi
Original Assignee
Fuji Oil Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Company, Limited filed Critical Fuji Oil Company, Limited
Priority to JP2004505036A priority Critical patent/JP4479505B2/ja
Priority to AU2003244099A priority patent/AU2003244099A1/en
Publication of WO2003097037A1 publication Critical patent/WO2003097037A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Definitions

  • the present invention relates to an allergy symptom relieving agent. Background technology
  • Hay fever and food allergies are classified as type I allergies.
  • type I allergy two allergen-specific IgE antibody molecules bind to the high-affinity IgE receptor on the surface of mast cells and are cross-linked by newly invaded allergens, resulting in chemical mediators such as histamine and leukotriene. Is caused by the release of Chemical mediators are intercellular messengers involved in the inflammatory response that are originally retained in cells and released out of cells in response to stimulation (histamine, heparin, etc.) However, there are new ones that are produced in response to the stimulus (such as oral trojans and prostaglandins).
  • leukotriene is a group of biologically active substances synthesized in animal tissues from eicosabolienic acid such as arachidonic acid.
  • Oxygen molecules are added to the carbon atom at the 5-position of arachidonic acid by the action of lipoxygenase to produce 5-hydroperoxide, followed by LTA 4 containing 5,6-epoxide.
  • LTA 4 containing 5,6-epoxide.
  • double bond contains hydrate port hexyl groups from water 1 2-position carbon atom are sequentially moved, 5, 1 and was the 2 dihydric Dorikishiru body is LTB 4.
  • teas such as green tea, black tea, and tea
  • lipophenols such as epigallocatechin gallate, epipicatechin gallete, epigallocatechin, and X picatechin contained in various natural materials such as ginkgo biloba and propolis.
  • flavonoids such as kenferol, quercetin, myricetin, and luteolin have been found to have chemical mediator release inhibitory activity, but the number of patients complaining of allergic symptoms in recent years has been increasing Therefore, the development of more active ingredients is required.
  • the present invention provides an allergic symptom-alleviating agent. Disclosure of the invention
  • the present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, have found that isoflavones contained in soybeans, radish and the like have an activity of suppressing the release of chemical media every night and can be applied to alleviation of allergic symptoms. As a result, the present invention was completed.
  • An allergic symptom-alleviating agent which comprises a metabolite of isoflavones alone or the metabolite and isoflavones as active ingredients.
  • the allergic symptom relieving agent of the present invention is characterized by using isoflavones and metabolites thereof as active ingredients.
  • the isoflavones that are the active ingredients of the present invention include isoflavone glycosides (daizin or genidin). Stin or their acetyl or malonyl derivatives) and isoflavone glycones (daidzein, genistein, etc.). In vivo, it is preferable to use isoflavone aglycone which acts directly.
  • the metabolites of isoflavones are equol, dehydroequol, 0-desmethylangorensin, 2-dehydro 0-desmethylangorensin, 6-hydroxyl 0-desmethylangorensin, and dihydro.
  • Daidzein, dihydrogenistin, tetrahydrodizein and the like can be used. More preferably, it is appropriate to use equol which is a metabolite of daidzein.
  • isoflavone glycosides are also metabolized to isoflavone glycoconjugates in vivo, and thus can be used as an allergy symptom relieving agent.
  • the allergic symptom-relieving effect of the present invention is due to the activity of inhibiting the release of chemical mediators such as histamine, leukotriene, platelet activating factor (PAF), prostaglandin, and tropoxane. , a strong release suppression activity in particular against the leuco Toryen (L TA 4, L TB 4, etc.).
  • chemical mediators such as histamine, leukotriene, platelet activating factor (PAF), prostaglandin, and tropoxane.
  • the active ingredient of the present invention can be obtained as a high-concentration extract by extracting the active ingredient from isoflavone-containing plants such as soybeans and clover by a known method.
  • the method is not particularly limited, but for example, it can be prepared in the following manner.
  • Soybeans as raw materials for preparing the active ingredient of the present invention include, for example, whole soybean, dehulled soybean, dehulled dehypocotyl soybean, soybean hypocotyl, defatted soybean, isolated soybean protein, concentrated soybean protein, soymilk , Okara, and soybean whey.
  • the content of isoflavones is high, JP03 / 06241
  • soybean hypocotyl having a high ratio of daidzin and its malonyl form and acetyl form.
  • soybeans as described above or after pulverization are extracted with a polar solvent such as water, methanol, ethanol or propanol to obtain a soybean extract.
  • a polar solvent such as water, methanol, ethanol or propanol
  • This extract may be used as an active ingredient as it is, or the extract may be further purified in order to obtain an allergic symptom-relieving action with a small amount of ingestion.
  • purification method purification by column chromatography using anion exchange resin or synthetic adsorption resin or the like, or purification by liquid-liquid distribution method using an organic solvent such as ptanol is used.
  • soybean extract should contain / 3—glycosidase or
  • An aglycone-rich fraction can be obtained by reacting various enzyme agents or microbial cells (such as Bacillus natto, lactic acid bacteria, and Aspergillus) with glycosidase and decomposing daidzin and genistin into daidzin and genistein. This fraction can be used to obtain pure Daisen and Genistin by column chromatography. '
  • the soybean extract containing these active ingredients may be applied as it is as a daidzein or genistein-containing fraction, or may be processed into a concentrated solution or a dry powder.
  • metabolites of isoflavones such as equol can be obtained by a reduction reaction of chemically synthesizing and enzymatic hydrogenation using the soybean extract, daidzein, and genistein as substrates (for example, WO OO /
  • it can also be obtained by a fermentation method using isoflavones assimilating microorganisms (for example, International Publication W099 / 07392).
  • the active ingredients of the present invention described above include histamine and leukotriene. It has the effect of suppressing the release of Chemical Medicaine, a substance that causes allergic symptoms, into the body, and has an excellent allergy-alleviating effect. It is useful as a health food application.
  • a composition in a unit dosage form suitable for administration may be prepared.
  • a dosage form suitable for oral administration a solid preparation such as a tablet, a pill, a capsule, or a granule may be formulated according to an ordinary method, and a coating may be applied.
  • liquid preparations such as emulsions, solutions, suspensions, and syrups may be produced according to a conventional method and used as liquid preparations.
  • Examples of the form in which the active ingredient of the present invention is used as an additive in edible compositions such as health foods include various forms suitable for beverages (liquids, powders), confectionery, processed foods, seasonings and the like. It is possible, and there is no particular limitation.
  • a sweetener, a seasoning, an excipient, an emulsifier, a colorant, a flavor, a stabilizer, and the like, which are usually used for making an edible composition, may be blended as needed and produced.
  • the drug and the edible composition of the present invention are polyphenols such as epigallocatechin gallate, epipicatechin gallate, epigallocatechin, eppicatechin, and the like, which are considered to be effective in alleviating allergic symptoms, kenferol, quercetin, miepetine It is of course possible to obtain synergistic effects by incorporating flavonoids such as lisetine and luteolin and other active ingredients.
  • the dose of the allergic symptom-mitigating agent in the present invention varies depending on the condition, age, body weight, etc., and the administration method of the subject, but is usually an active ingredient.
  • a daily dose of 10 mg to 1000 mg should be taken. You can take the required amount once a day or multiple times as needed.
  • genistin, daidzin, genistein and daidzein were purchased from Fujico and Equol from Apin Chemicals.
  • Calcium ionophores A23187 and LTB 4 were purchased from Sigma, and prostaglandin B2 (PGB 2 ) was purchased from Cayman Chemical Company.
  • Tyrode's buffer (pH 7.4) was prepared as a 137 mM NaCl, 2.7mM KCK 1.8 mM CaCl have l. O mM MgCl physician 12 mM NaHCO physician 0.4 mM NaH 2 P0 4.
  • a Tyrode buffer containing 0.1% D-glucose, 0.1% fish gelatin (Sigma) and 0.1% Pserum serum albumin was injected into the abdominal cavity of a male Sprague-Dawley rat (8-19 weeks old). After gently massaging the abdomen for 2 minutes, the abdomen was opened to collect Tyrode buffer containing PEC. This Tyrode buffer was centrifuged at 200 g at 4 t: for 5 minutes, and the supernatant was removed to obtain a cell pellet.
  • ni-ACT 150 mM NH 4 C1, 10 mM KHC0 3, 10 mM EDTA_2Na, pH 7.4
  • This cell suspension was further centrifuged at 4 ° C and 200G for 5 minutes to remove the supernatant, and resuspended in Tyrode's buffer so that the cell count was 2 ⁇ 10 6 cells / ml. . • Measurement of LTB 4 emissions
  • the supernatant was centrifuged 10 min at 10,000 G was filtered through a fill evening one was analyzed LTB 4 content in the supernatant at a high speed liquid chromatography.
  • the sample solution 20 1 0DS- ⁇ force ram (150X6.0 mm, 5 ⁇ 1, article size 5 ⁇ , YMC) subjected to, mobile phase Asetonitoriru: methanol Ichiru: 5 mM CH 3 C00NH 4 ( pH 5.6) ( 30:25:45, vol / vol / vol) and the flow rate was 1.1 ml / min.
  • LTB 4 and internal standard PGB 2 is Absorbance at 280 nm (SPD 10AVP, Shimadzu) it detects in. Advance a calibration curve from the peak area of LTB 4 of known amount, determine the LTB 4 emissions.
  • a novel allergy symptom-mitigating agent containing isoflavones having low side effects extracted or purified from natural soybeans or the like as active ingredients can be provided. It can also provide a new method of effective use of sosoflavone isoflavone, which can contribute to the allergic and soybean related industries.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle substance atténuant les symptômes allergiques dérivée de produits naturels et permettant d'apaiser les inquiétudes quant aux effets secondaires de certains médicaments, et notamment de médicaments synthétiques. Plus particulièrement, l'invention concerne une substance atténuant les symptômes allergiques comprenant un métabolite d'isoflavone, tel que l'équol, comme ingrédient actif, ladite substance inhibant efficacement la libération de médiateurs chimiques.
PCT/JP2003/006241 2002-05-20 2003-05-19 Substance attenuant les symptomes allergiques WO2003097037A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004505036A JP4479505B2 (ja) 2002-05-20 2003-05-19 アレルギー症状緩和剤
AU2003244099A AU2003244099A1 (en) 2002-05-20 2003-05-19 Allergic symptom reliever

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002/144050 2002-05-20
JP2002144050 2002-05-20

Publications (1)

Publication Number Publication Date
WO2003097037A1 true WO2003097037A1 (fr) 2003-11-27

Family

ID=29545046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/006241 WO2003097037A1 (fr) 2002-05-20 2003-05-19 Substance attenuant les symptomes allergiques

Country Status (3)

Country Link
JP (1) JP4479505B2 (fr)
AU (1) AU2003244099A1 (fr)
WO (1) WO2003097037A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006348003A (ja) * 2005-06-20 2006-12-28 Sanei Gen Ffi Inc マスト細胞ＩｇＥレセプター発現抑制剤
WO2008126752A1 (fr) 2007-04-09 2008-10-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent d'éclaircissement de la peau contenant un composé d'équol en tant que principe actif
JP2016196428A (ja) * 2015-04-03 2016-11-24 株式会社ダイセル エクオール及びキレート剤を含有する外用組成物
JP2016196427A (ja) * 2015-04-03 2016-11-24 株式会社ダイセル エクオール、酸化防止剤、及び油類を含有する外用組成物
JP2021106606A (ja) * 2007-06-13 2021-07-29 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016196430A (ja) * 2015-04-03 2016-11-24 株式会社ダイセル エクオール及び保湿剤を含有する外用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (ja) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc 抗アレルギ−剤
JPH0368515A (ja) * 1989-08-08 1991-03-25 Tsumura & Co 抗アレルギー剤
JP2003002811A (ja) * 2001-11-07 2003-01-08 Naris Cosmetics Co Ltd ＩｇＥ産生抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (ja) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc 抗アレルギ−剤
JPH0368515A (ja) * 1989-08-08 1991-03-25 Tsumura & Co 抗アレルギー剤
JP2003002811A (ja) * 2001-11-07 2003-01-08 Naris Cosmetics Co Ltd ＩｇＥ産生抑制剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATLURU, D ET AL: "Genistein, a selective protein tyrosine kinase inhibitor inhibits interleukin-2 and leukotriene B4 production from human mononuclear cells.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 59, no. 3, 1991, pages 379 - 387, XP002973174 *
HODEK, P ET AL: "Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450.", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 139, no. 1, 2002, pages 1 - 21, XP002973172 *
PARK, KWANHA ET AL: "Anti-asthmatic compound with leukotriene D4 antagonism isolated from Pueraria radix", J. KOREAN SOC. AGRIC. CHEM. BIOTECHNOL., vol. 44, no. 1, 2001, pages 38 - 39, XP002975627 *
PIETTA, PIER-GIORGIO: "Flavonoids as Antioxidants.", J. NAT. PROD., vol. 63, 2000, pages 1035 - 1042, XP002973173 *
VEDAVANAM, K ET AL: "Antioxidant action and potential antidiabetic properties of an isoflevonoid-containing soyabean phytochemical extract spe", P=HYTOTHERAPY RESEARCH, vol. 13, no. 7, 1999, pages 601 - 608, XP002973175 *
WONG, W ET AL: "Effects of Tyrosine Kinase Inhibitors on Antigen Challenge of Guinea Pig Lung in Vitro.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 283, no. 1, 1997, pages 131 - 137, XP000891663 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006348003A (ja) * 2005-06-20 2006-12-28 Sanei Gen Ffi Inc マスト細胞ＩｇＥレセプター発現抑制剤
WO2008126752A1 (fr) 2007-04-09 2008-10-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent d'éclaircissement de la peau contenant un composé d'équol en tant que principe actif
JP2022078239A (ja) * 2007-06-13 2022-05-24 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7087217B2 (ja) 2007-06-13 2022-06-20 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2021106606A (ja) * 2007-06-13 2021-07-29 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7009044B1 (ja) 2007-06-13 2022-01-25 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7009043B2 (ja) 2007-06-13 2022-01-25 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7019279B1 (ja) 2007-06-13 2022-02-15 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2022037077A (ja) * 2007-06-13 2022-03-08 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2022044055A (ja) * 2007-06-13 2022-03-16 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7354470B2 (ja) 2007-06-13 2023-10-02 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7309312B2 (ja) 2007-06-13 2023-07-18 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2022119999A (ja) * 2007-06-13 2022-08-17 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7121872B1 (ja) 2007-06-13 2022-08-18 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7255036B1 (ja) 2007-06-13 2023-04-10 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP7271804B1 (ja) 2007-06-13 2023-05-11 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2023071873A (ja) * 2007-06-13 2023-05-23 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2023071874A (ja) * 2007-06-13 2023-05-23 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2023082097A (ja) * 2007-06-13 2023-06-13 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2023093697A (ja) * 2007-06-13 2023-07-04 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
JP2016196427A (ja) * 2015-04-03 2016-11-24 株式会社ダイセル エクオール、酸化防止剤、及び油類を含有する外用組成物
JP2016196428A (ja) * 2015-04-03 2016-11-24 株式会社ダイセル エクオール及びキレート剤を含有する外用組成物

Also Published As

Publication number Publication date
AU2003244099A1 (en) 2003-12-02
JP4479505B2 (ja) 2010-06-09
JPWO2003097037A1 (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
EP1906944B1 (fr) Preparation de schisandrine b
EP1137429A2 (fr) Methode d'inhibition des cyclooxygenases et des inflammations au moyen de bioflavonoides de cerises
CA2592279A1 (fr) Composition de glycosides de quercetine et procede de preparation de celle-ci
CN108697685A (zh) 含有桑辛素、桑黄铜g或桑白皮的，肌肉疾病的预防及治疗用或肌功能改善用组合物
JP5842640B2 (ja) ホスホジエステラーゼ３阻害剤
JP5466842B2 (ja) グルタチオン産生促進組成物
JP2009155293A (ja) 発酵甘草抽出物及びその製造方法、並びに、発酵甘草抽出物を含有する皮膚外用剤及び美容用飲食品
JP2009269889A (ja) グルタチオン産生促進剤、グルタチオンの欠乏に起因する疾患の予防・治療剤及び飲食品
WO2003097037A1 (fr) Substance attenuant les symptomes allergiques
JP6211406B2 (ja) ムスカリン受容体活性化剤及び唾液分泌促進剤
JP2024010170A (ja) エクオール含有組成物の製造方法
JP2007197398A (ja) アレルギー症状予防／治療用経口組成物
JP4813771B2 (ja) 血管内皮型一酸化窒素合成酵素活性促進剤
KR100794610B1 (ko) 디벤조-ｐ-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품
JP2006241039A (ja) ウレアーゼ阻害剤
JP2011032187A (ja) ローヤルゼリー抽出物及びヒト骨芽細胞増殖抑制剤
EP1679079A1 (fr) Composition d'extrait de graines vegetales et procede pour la produire
JP2009137920A (ja) グリコーゲンホスホリラーゼ阻害剤
Choi et al. Characteristics of fermentation and bioavailability of isoflavones in Korean soybean paste (doenjang) with application of Bacillus sp. KH‐15
JP3250071B2 (ja) 抗骨粗鬆症組成物
KR20120044450A (ko) 대계 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
JP2003026584A (ja) 肝臓疾患治療剤
JP2006016340A (ja) ザクロ抽出物を有効成分とする、血中尿酸値低下剤
KR102468526B1 (ko) 녹용 추출물 또는 강글리오사이드를 유효성분으로 함유하는 환경오염인자로부터 유도되는 방향족 탄화수소 수용체 매개성 질환의 예방 또는 치료용 조성물
JP7376889B2 (ja) Ｕｒａｔ１阻害剤及びｕｒａｔ１阻害用飲食品組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004505036

Country of ref document: JP

122 Ep: pct application non-entry in european phase